He's probably referring to this article: https://news.ycombinator.com/item?id=39405547 that made the rounds a few weeks ago, and bungled the meaning ("executive compensation / stock" rather than "executives and stockholders than on R&D").
Correct. I see this from the perspective of the society overall. I do not care whether the money goes to the CEO, a mid-level executive, a sales rep or the stock divident/buyback etc. What matters is how much money from the dollar I spend on a drug goes to research and how much into cost of production. Every other cent is something which has to be under scrutiny like is any tax dollar. Healthcare is like water, food, and shelter an elementary human need. Excessive profiteering or waste on it is just wrong.
